A Comparative Analysis of Insulin Glargine and New Insulin Analog LY IGlar in Diabetes Treatment
DOI:
https://doi.org/10.61173/mzrj3565Keywords:
Insulin glargine (IGlar), LY29630160(LY IGlar), Diabetes, Clinical efficacy, SafetyAbstract
This review compares insulin glargine (IGlar) and the new insulin analog LY IGlar in diabetes treatment. IGlar, a long-acting insulin analog, has been widely used clinically. Insulin glargine LY29630160 (LY IGlar) has a special chemical structure with potential advantages like a longer half-life and improved absorption. Clinical studies show comparable blood sugar control efficacy between the two, with LY IGlar having a potentially lower hypoglycemia risk. They have similar effects on blood glucose regulation and other side effects. Dosing differences of LY IGlar may simplify regimens, and patient feedback varies. Future research needs larger and longer studies to address limitations and explore combination therapies and cost-effectiveness.
References
[1] Mayer JP, Zhang F, DiMarchi RD. Insulin structure and function. Biopolymers, 2007,88(5):687-713.
[2] Ampudia-Blasco FJ. Biosimilars and Novel Insulins. Am J Ther, 2020,27(1):e52-e61.
[3] Davies M, Dahl D, Heise T, Kiljanski J, Mathieu C. Introduction of biosimilar insulins in Europe. Diabet Med, 2017,34(10):1340-1353.
[4] Ampudia-Blasco FJ. Biosimilars and Novel Insulins. Am J Ther, 2020;27(1): e52-e61.
[5] Qun Liu, Ming-liang Zhu, Qiu-yang Jin, et al. Metaanalysis of clinical efficacy and safety of generic and original insulin glargine for type 2 diabetes mellitus[J]. Central South Pharmacy,2024,22(06):1668-1673.
[6] Altman, J. J., Chevalier, N., Delemer, B., Travert, F., & Benabbad, I. (2018). Développement des biosimilaires de l’insuline : exemple de l’insuline glargine LY2963016 [LY2963016 insulin glargine: The first biosimilar insulin approved in the European Union]. Presse medicale (Paris, France Dean&Francis Zicheng Wang : 1983), 2018,47(10): 854–866.
[7] Lamb YN, Syed YY. LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes. BioDrugs, 2018 ,32(1):91-98.
[8] Hilgenfeld R, Seipke G, Berchtold H, Owens DR. The evolution of insulin glargine and its continuing contribution to diabetes care. Drugs 2014,74: 911–927.
[9] Linnebjerg H, Lam EC, Seger ME, et al. Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp Studies. Diabetes Care, 2015,38(12):2226-2233.
[10] Yan X, Feng C, Lou Y, Zhou Z. Efficacy and Safety of LY2963016 Insulin Glargine in Chinese Patients with Type 1 Diabetes Previously Treated with Insulin Glargine (Lantus® ): a Post Hoc Analysis of a Randomized, Open-Label, Phase 3 Trial. Diabetes Ther, 2022;13(6):1161-1174.
[11] Blevins TC, Dahl D, Rosenstock J, et al. Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study. Diabetes Obes Metab, 2015;17(8):726-733.
[12] Rosenstock J, Hollander P, Bhargava A, et al. Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study). Diabetes Obes Metab, 2015;17(8):734-741.
[13] Lin-lang Liang. To discuss the clinical application of insulin from the “imitation” of the original insulin [J]. Evaluation of drugs, 2022,19(04):193-197.
[14] Eli Lilly and Company. US prescribing information for Basaglar (insulin glargine injection), for subcutaneous use. 2016. http://pi. lilly.com/. Accessed 9 Jan 2018.
[15] Yki-Jarvinen H, Dressler A, Ziemen M, HOE 901/3002 Study Group. Less noctur nal hypoglycemia and better postdinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination ther apy in type 2 diabetes. Diabetes Care 2000, 23: 1130–1136.
[16] Shiramoto M, Eto T, Irie S, et al. Single-dose new insulin glargine 300 U/ml provides pro longed, stable glycaemic control in Japanese and European people with type1 diabetes. Diabetes Obes Metab, 2015;17: 254–260
[17] Tieu C, Lucas EJ, DePaola M, Rosman L, Alexander GC. Efficacy and safety of biosimilar insulins compared to their reference products: A systematic review. PLoS One, 2018;13(4): e0195012.
[18] Sebastian SA, Co EL, Mehendale M, Hameed M. Insulin analogs in the treatment of type II diabetes and future perspectives. Dis Mon, 2023;69(3):101417.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
